PRTN3 and synovitis: Further pilot data showed that in a small cohort of ACPA+ arthralgia patients with no synovitis, only those within a few weeks (∼12) of developing clinical evidence of synovitis were positive for anti-ROS-CII reactivity while those who developed symptoms after a much longer delay were negative.